FDA approves Ceptaris' Valchlor, Actelion deal marches on

Actelion Ltd. (SIX:ATLN) said it is proceeding with its acquisition of Ceptaris Therapeutics Inc. (Malvern, Pa.) after FDA approved an NDA from Ceptaris for Valchlor mechlorethamine to treat stage IA and IB mycosis fungoides, a type of cutaneous T cell lymphoma (CTCL). The deal is contingent on undisclosed "minor" conditions. Last month, Actelion paid $25 million to Ceptaris in exchange for the right to acquire Ceptaris for $225 million, plus undisclosed milestones pending Valchlor's U.S. approval (see BioCentury Extra, July 31). ...